Cytokinetics (CYTK) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Cytokinetics (CYTK) over the last 10 years, with Q4 2024 value amounting to -$1.26.
- Cytokinetics' EPS (Weighted Average and Diluted) rose 9990.96% to -$1.26 in Q4 2024 from the same period last year, while for Dec 2024 it was -$5.26, marking a year-over-year increase of 9990.32%. This contributed to the annual value of -$5.26 for FY2024, which is 9990.32% up from last year.
- Cytokinetics' EPS (Weighted Average and Diluted) amounted to -$1.26 in Q4 2024, which was up 9990.96% from -$1.36 recorded in Q3 2024.
- In the past 5 years, Cytokinetics' EPS (Weighted Average and Diluted) ranged from a high of -$0.23 in Q2 2022 and a low of -$1394.3 during Q4 2023
- Its 5-year average for EPS (Weighted Average and Diluted) is -$148.34, with a median of -$1.35 in 2023.
- As far as peak fluctuations go, Cytokinetics' EPS (Weighted Average and Diluted) crashed by 9410847.02% in 2023, and later skyrocketed by 9990.96% in 2024.
- Cytokinetics' EPS (Weighted Average and Diluted) (Quarter) stood at -$626.51 in 2020, then soared by 46.19% to -$337.15 in 2021, then soared by 99.56% to -$1.48 in 2022, then crashed by 94108.47% to -$1394.3 in 2023, then skyrocketed by 99.91% to -$1.26 in 2024.
- Its EPS (Weighted Average and Diluted) stands at -$1.26 for Q4 2024, versus -$1.36 for Q3 2024 and -$1.31 for Q2 2024.